Introduction Pamidronate is the most widely used bisphosphonate to treat osteoporosis in children. It is commonly given IV for 3 consecutive days, for 5 orHtreatment fractures occur at the margins of pamidronate bands that form with bisphosphonate treatment in growing bone. A ramped dosing regimen was proposed to mediate stress-riser formation. Objectives Compare the effects of a ramped dosage schedule of pamidronate on BMD, fracture rate and location versus a uniform 5-course regimen. Methods Ten non-ambulatory children (7 females) with neuromuscular disabilities who received IV pamidronate with a tapering dose were identified (Group 1) and compared to a cohort of 25 similar patients who received a uniform 5-course regimen (Group 2). Periodic DXA evaluations were performed every 6 months. Fracture rate before and after treatment was calculated using the person-years method, with post-treatment observation starting with the first dose. Radiographs were examined for location of fracture. Results Over treatment, lumbar spine (LS) BMD increased 47.7% and lateral distal femur (LDF) BMD of all regions (R1, R2 & R3) increased 38.0%, 30.1%, and 22.9%, respectively. Group 2 BMD increases were 40.3% at LS and 68.3%, 15.6% and 10.8%, for LDF R1 – R3. Mean post-treatment observation period was 4.6 years. Two of 10 children in Group 1 sustained a fracture during treatment [right distal femur at 3 weeks, left foot at 10.5 months] but no fractures occurred after treatment ended. Pre and post-treatment fracture rates were 18.5% and 4.3%. Four of 25 in Group 2 sustained 5 fractures after treatment over the same time period; 80% occurred at pamidronate bands. Pre and post-treatment fracture rates in were 36% and 13% for Group 2. Conclusion Regardless of dosing schedule, BMD improved, post-treatment fracture rate decreased after treatment started, and fractures occurred during treatment. After treatment ended, no fractures occurred in those who received the ramped dosage, suggesting reduction in stress riser formation. A longer treatment period and greater total amount of drug administered with the ramped dose might be contributory. Further study of a ramped dosing schedule is warranted.
Read full abstract